Highlights 

  • Prime Medicine reports first-in-human data for its Prime Editing therapy PM359. 
  • NEJM publication showcases encouraging safety and clinical improvement in two CGD patients. 
  • Both patients demonstrated rapid and durable neutrophil recovery post-treatment. 
  • No PM359-related safety issues were observed in the Phase 1/2 study. 
  • Findings strengthen confidence in Prime Editing as a precise gene-repair platform. 

Prime Medicine (NASDAQ:PRME) has unveiled high-impact clinical results for PM359, its investigational autologous hematopoietic stem cell therapy for p47phox chronic granulomatous disease. The data represents the first clinical demonstration of Prime Editing in humans, signaling a potentially transformative step forward for gene-repair technologies. 

The Phase 1/2 study evaluated two patients—one adult and one pediatric—who had previously experienced CGD-related complications such as CGD-associated colitis and recurrent infections. Both were maintained on long-term prophylaxis prior to receiving PM359. The results showcase meaningful biological activity, early clinical benefit, and an encouraging safety profile. 

Demonstrated Biological Activity and Early Clinical Improvements 

Both trial participants achieved rapid neutrophil engraftment, with 69 percent and 83 percent DHR-positive neutrophils by Day 30—well above the projected 20 percent threshold associated with clinical benefit. Importantly, these levels remained stable over time, indicating durable gene correction within long-term repopulating hematopoietic stem cells. 

Clinical improvements were observed early. Neither patient experienced new CGD-related complications following infusion. One patient discontinued mesalamine with no recurrence of colitis, while the second patient experienced a marked decline in fecal calprotectin levels alongside relief from chronic CGD-associated colitis symptoms. 

On the safety front, PM359 did not produce any clinically meaningful adverse events. All observed toxicities aligned with expectations for busulfan-based conditioning, underscoring the therapy’s favorable tolerability to date. 

A Pivotal Moment for Prime Editing as a Therapeutic Platform 

According to Prime Medicine’s Chief Medical Officer, Dr. Mohammed Asmal, the findings highlight the potential advantages of Prime Editing over traditional gene-editing methods. Because Prime Editing does not induce double-strand DNA breaks, it may be more compatible with sensitive cell types such as hematopoietic stem cells. 

Prime Medicine continues to advance a pipeline spanning liver, lung, immunology, and oncology applications. With PM359 now demonstrating encouraging initial clinical results, the platform’s versatility and precision open the door to treating thousands of potential genetic conditions. 

Conclusion 

Prime Medicine’s NEJM publication marks a pivotal moment for the gene-editing field. The company’s early clinical data show encouraging safety, meaningful biological correction, and improved clinical outcomes in patients with p47phox CGD. As the trial progresses, PM359 has the potential to redefine how inherited immunodeficiencies are treated and strengthen Prime Editing’s position as a next-generation gene-repair approach. 

Prime Medicines’ shares closed at USD 3.75, marking a 3.10% decrease from the prior session.